Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IRX 4310

Drug Profile

IRX 4310

Alternative Names: AGN-194310; AGN-4310; ALRT-4310; LGD-4310; NRX-4310

Latest Information Update: 19 Apr 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Allergan; Ligand Pharmaceuticals
  • Developer Allergan; Io Therapeutics
  • Class Antipsoriatics; Benzoic acids; Thiophenes
  • Mechanism of Action Retinoic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neutropenia
  • Discontinued Acne; Atopic dermatitis; Psoriasis; Xerostomia

Most Recent Events

  • 19 Apr 2016 No recent reports on development identified - Preclinical for Neutropenia (Chemotherapy-induced) in USA (PO)
  • 06 Oct 2011 Discontinued - Phase-II for Acne in United Kingdom (unspecified route)
  • 06 Oct 2011 Discontinued - Phase-III for Atopic dermatitis in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top